Memantine Clonmel

Memantine, the active ingredient in Memantine Clonmel, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the symptomatic treatment of moderate to severe Alzheimer’s disease in adult patients, helping to improve cognition and daily functioning.

GNH USA supplies Memantine Clonmel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to EU quality standards and is manufactured under GMP conditions. It is distributed through a secure logistics network ensuring product integrity.

Memantine acts on the glutamatergic pathway and is used in the management of Alzheimer’s disease.

Alzheimer's disease (mild to moderate): used in combination with cholinesterase inhibitors to support cognition. Alzheimer's disease (moderate to severe): used as monotherapy to improve cognitive function and daily activities. Behavioral symptoms of Alzheimer’s disease: may help reduce agitation and improve patient cooperation when combined with other therapies.

Memantine may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness - Headache - Constipation - Confusion - Fatigue

Serious or Rare Side Effects: - Seizures - Severe allergic reactions (rash, swelling, difficulty breathing) - Hallucinations or psychotic symptoms - Suicidal thoughts or behavior

When prescribing memantine, clinicians should consider several precautionary measures to ensure safe use.

- Renal impairment: adjust dose or monitor renal function in patients with reduced kidney clearance. - History of seizures: monitor closely as memantine may lower seizure threshold. - Concurrent NMDA agonists: avoid co‑administration due to opposing pharmacologic effects. - Pregnancy: use only if potential benefit justifies potential risk to the fetus. - Elderly patients: monitor for increased confusion or worsening cognition. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Memantine can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase central nervous system side effects. - Ketamine: additive NMDA blockade can lead to excessive sedation or respiratory depression. - Strong CYP450 inducers (e.g., carbamazepine, rifampicin): may reduce memantine plasma concentrations.

Moderate Interactions (Monitor Closely): - Anticholinesterase inhibitors (e.g., donepezil): may increase risk of dizziness or hypotension. - Diuretics (e.g., furosemide): may elevate memantine serum levels, requiring monitoring. - Alcohol: concurrent use may enhance central nervous system depression.